Eli Lilly & Co. has received approval from European regulators for its Alzheimer's disease PET imaging agent Amyvid. The move allows the use of the agent in adults with cognitive impairment who are being assessed for Alzheimer's and related conditions. The agent should be available in Europe in the second quarter of the year.

Full Story:

Related Summaries